Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Tonix Pharma ( (TNXP) ) just unveiled an announcement.
On July 9, 2025, Tonix Pharmaceuticals announced the publication of full results from its Phase 3 RESILIENT trial for TNX-102 SL in the journal Pain Medicine. This development could enhance the company’s positioning in the fibromyalgia treatment market by providing evidence of the product’s efficacy, potentially impacting stakeholders positively.
The most recent analyst rating on (TNXP) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
Spark’s Take on TNXP Stock
According to Spark, TipRanks’ AI Analyst, TNXP is a Neutral.
Tonix Pharma’s overall stock score is driven by strong technical indicators and positive corporate events, which are partially offset by financial performance challenges and poor valuation metrics. The company’s growth potential in the biotechnology sector, supported by recent corporate developments, is a key strength.
To see Spark’s full report on TNXP stock, click here.
More about Tonix Pharma
Tonix Pharmaceuticals Holding Corp. operates in the pharmaceutical industry, focusing on developing innovative therapies for central nervous system disorders, immunology, and infectious diseases. Its primary product candidates include TNX-102 SL, a sublingual tablet for fibromyalgia management.
Average Trading Volume: 885,926
Technical Sentiment Signal: Sell
Current Market Cap: $260.7M
Learn more about TNXP stock on TipRanks’ Stock Analysis page.